NNZ-2591, a Synthetic IGF-1 Metabolite Analog: Phase 2 Clinical Trial Results for Children and Adolescents With Pitt Hopkins SyndromeLikeFollowShareShare your feedbackQuestions (0)Post questionYour question will be sent privately to Neuren Pharmaceuticals. The company may choose to make this question public.Start the conversationAsk Neuren Pharmaceuticals a question about this update.DiscoverShare your feedbackDiscover
